glp-1 receptor agonists and sglt2 inhibitors in Diabetic Kidney Disease: Evolving Evidence and Clinical Application Effects of Pharmacologic Therapy for
Description
Metseras pipeline includes MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, and MET-233i, an amylin analog being developed for monthly administration
DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006
Starting today, eligible Medicare patients living with obesity can access Wegovy (semaglutide) injection and pill for a $50 monthly copay Wegovy offers...
Subtle support that works with your habits, not against them
The platform, called LillyDirect, joins a growing field of websites offering telehealth prescriptions for weight loss drugs.
Standards of Care in Diabetes2025
